Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dr Reddy’s Debuts US Vimovo Rival At Risk

Lupin Has Authorized Generic As Nuvo Cites Patents To 2022

Executive Summary

Dr Reddy’s has announced the launch of the first US generic version of Vimovo delayed-release tablets. However, Nuvo has warned that the at-risk launch infringes patents protecting the arthritis pain treatment until May 2022.

You may also be interested in...



Federal Circuit Rules In Favor Of Reddy’s Again On Vimovo

Dr Reddy’s Laboratories has once again prevailed over Horizon Pharma and Nuvo in litigation over patents shielding the originators’ Vimovo, with the US Court of Appeals for the Federal Circuit affirming a lower court's invalidity ruling.

Reddy’s Will Look For Acquisitions Under New CEO Israeli

With Erez Israeli set to step up from COO to CEO, Dr Reddy’s is looking to leverage its lack of debt and strong cash flow in the mergers and acquisitions arena.

Reddy’s, Lupin And Mylan Clear Two Vimovo Patents From Path

Three generics players in the US have helped to clear the path for generic rivals to the Vimovo analgesic by winning an appeals verdict of written descriptions for two patents.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149680

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel